Your browser doesn't support javascript.
loading
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
Tuffy, Kevin M; Ahani, Bahar; Aksyuk, Anastasia A; Avila, Miles; Brady, Tyler; Kijak, Gustavo H; Koh, Gavin; Levin, Myron J; Roe, Tiffany L; Schuko, Nicolette; Thissen, Jesse; Ustianowski, Andrew; Zhang, Tianhui; Kelly, Elizabeth J; Streicher, Katie.
Afiliação
  • Tuffy KM; Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, Maryland, USA.
  • Ahani B; Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, Maryland, USA.
  • Aksyuk AA; Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, Maryland, USA.
  • Avila M; Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, Maryland, USA.
  • Brady T; Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, Maryland, USA.
  • Kijak GH; Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, Maryland, USA.
  • Koh G; Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, United Kingdom.
  • Levin MJ; University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Roe TL; Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, Maryland, USA.
  • Schuko N; Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, Maryland, USA.
  • Thissen J; Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Cambridge, United Kingdom.
  • Ustianowski A; North Manchester General Hospital, Manchester, United Kingdom.
  • Zhang T; Discovery Sciences, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, Maryland, USA.
  • Kelly EJ; Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, Maryland, USA.
  • Streicher K; Vaccines and Immune Therapies, BioPharmaceuticals Research and Development, AstraZeneca, Gaithersburg, Maryland, USA.
J Infect Dis ; 228(8): 1055-1059, 2023 10 18.
Article em En | MEDLINE | ID: mdl-37280116
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: J Infect Dis Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 Tipo de estudo: Risk_factors_studies Limite: Humans Idioma: En Revista: J Infect Dis Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos